Form 4: Altimmune Chief Medical Officer, Matthew Scott Harris, Reports Stock Transactions

Altimmune's Chief Medical Officer, Matthew Scott Harris, reported the vesting of restricted stock units and the grant of new stock options.

Summary

• Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., reported transactions involving the company's stock on January 25, 2025 and January 27, 2025.
• On January 25, 2025, 14,600 restricted stock units (RSUs) vested, resulting in the acquisition of 14,600 shares of common stock.
• Also on January 25, 2025, 4,994 shares were surrendered to cover taxes associated with the vesting of the RSUs.
• On January 27, 2025, Mr. Harris was granted 183,600 stock options with an exercise price of $7.00.
• Additionally, on January 27, 2025, Mr. Harris was granted 63,400 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects routine executive compensation transactions, which are generally viewed positively as they align management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The vesting of restricted stock units and the grant of new stock options indicate continued alignment of the executive's interests with those of the company and its shareholders.
• The grant of stock options at an exercise price of $7.00 suggests the company believes the stock price has the potential to increase above this level.

Negatives

• The surrender of 4,994 shares to cover taxes associated with the vesting of RSUs resulted in a reduction of Mr. Harris's direct holdings.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of RSUs is contingent on the reporting person's continued service with the company.

Future Outlook

The stock options granted on January 27, 2025 vest over time, with 25% vesting on January 27, 2026 and the remaining 75% vesting in equal monthly installments over the following 36 months. The RSUs granted on January 27, 2025 vest in equal annual installments over 4 years.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when officers and directors have transactions in the company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants and restricted stock unit vesting are common forms of compensation for executives in the biotechnology industry.
• The vesting schedules described are typical for equity compensation packages, designed to incentivize long-term performance and retention.
• The exercise price of $7.00 for the stock options is a common practice, often set at or above the current market price at the time of grant.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of management's commitment to the company's long-term success.
• The vesting of RSUs and stock options could potentially increase the number of shares outstanding over time.

Next Steps

• The stock options will vest over time, subject to the reporting person's continued service.
• The restricted stock units will vest over time, subject to the reporting person's continued service.

Key Dates

Keywords

Altimmune, stock options, restricted stock units, insider trading, Form 4, Matthew Scott Harris, equity compensation, vesting